<?xml version="1.0" encoding="UTF-8"?>
<p>Adenoviral vectors have previously been used to improve immunogenicity with excellent results in the enhancement of both humoral and cellular immunity [
 <xref rid="B57" ref-type="bibr">57</xref>]. ChAdOx1 85A has been contemplated as a TB vaccine first in healthy vaccinated BCG adults (Phase I Trial to Evaluate the Safety and Immunogenicity of a ChAdOx1 85A Vaccination with and without MVA85A Boost in Healthy BCG Vaccinated Adults, 
 <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01829490" xmlns:xlink="http://www.w3.org/1999/xlink">NCT01829490</ext-link>) and most recently with an ongoing trial in healthy adults with or without prior BCG vaccination (A Phase I Clinical Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine ChAdOx1 85A Administered by the Aerosol Inhaled Route and the Intramuscular Route in Healthy Adult Subjects, 
 <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04327206" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04121494</ext-link>).
</p>
